A quality initiative focused on BRCA and HRD testing and use of first line maintenance in advanced ovarian cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This ...

“Therefore, BRCA -like status may serve as a predictive biomarker in this patient population. The benefits of the BRCA- like classifier include a lower dropout rate and a larger group of patients with ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Homologous Recombination Deficiency (HRD) is a biomarker that enables the prediction of breast cancer treatment with first-line platinum-based chemotherapy or ovarian cancer treatment with PARP ...

Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, ...

BARCELONA, Spain & MONTPELLIER, France--(BUSINESS WIRE)--SeqOne, provider of new generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD ...

Starting in 2014, poly (ADP-ribose) polymerase inhibitors (PARPi) have been approved for the treatment of BRCA-mutated (BRCAm) and/or homologous recombination deficiency (HRD)-positive ovarian cancer, ...

The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase ...

Testing to measure homologous repair deficiency (HRD) in certain cancers can identify patients who may benefit from poly(ADP-ribose) polymerase inhibitors. We examined real-world patterns and factors ...

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at ...